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Abstract 
Background: Synaptic degeneration and accumulation of amyloid β‑peptides (Aβ) are hallmarks of the Alzheimer 
diseased brain. Aβ is synaptotoxic and produced by sequential cleavage of the amyloid precursor protein (APP) by the 
β‑secretase BACE1 and by γ‑secretase. If APP is instead cleaved by the α‑secretase ADAM10, Aβ will not be gener‑
ated. Although BACE1 is considered to be a presynaptic protein and ADAM10 has been reported to mainly localize 
to the postsynaptic density, we have previously shown that both ADAM10 and BACE1 are highly enriched in synaptic 
vesicles of rat brain and mouse primary hippocampal neurons.
Results: Here, using brightfield proximity ligation assay, we expanded our previous result in primary neurons and 
investigated the in situ synaptic localization of ADAM10 and BACE1 in rat and human adult brain using both pre‑ and 
postsynaptic markers. We found that ADAM10 and BACE1 were in close proximity with both the presynaptic marker 
synaptophysin and the postsynaptic marker PSD‑95. The substrate APP was also detected both pre‑ and postsynapti‑
cally. Subcellular fractionation confirmed that ADAM10 and BACE1 are enriched to a similar degree in synaptic vesicles 
and as well as in the postsynaptic density.
Conclusions: We show that the α‑secretase ADAM10 and the β‑secretase BACE1 are located in both the pre‑ and 
postsynaptic compartments in intact brain sections. These findings increase our understanding of the regulation of 
APP processing, thereby facilitating development of more specific treatment strategies.
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Background
Alzheimer disease (AD) is a slowly progressive neuro-
degenerative disorder leading to impairment in mem-
ory and other cognitive functions [1]. In the Alzheimer 
diseased brain, abnormal aggregation of the amyloid 
β-peptide (Aβ) leads to the formation of senile plaques. 
Together with neurofibrillary tangles of hyperphospho-
rylated tau, these plaques form the characteristic patho-
logical hallmarks of AD [2]. Aβ has also been shown to 
cause synaptic dysfunction and degeneration [3–5], 
which are among the earliest pathological events during 
the course of the disease and correlate well with cogni-
tive decline [1, 6]. The synaptotoxicity is particularly 
prominent for oligomeric forms of Aβ and might affect 
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neuronal function long before the appearance of plaques 
[2, 7].
Aβ is produced from the amyloid precursor pro-
tein (APP) by sequential cleavage performed by β- and 
γ-secretase. Non-amyloidogenic cleavage of APP by 
α-secretase instead of β-secretase precludes Aβ forma-
tion since the α-secretase cleavage site of APP is located 
within the Aβ sequence [2]. The β-site APP cleaving 
enzyme 1 (BACE1) is the main β-secretase of neurons 
[8–12] while α-cleavage mainly is performed by a dis-
integrin and metalloproteinase 10 (ADAM10) [13, 14]. 
BACE1 levels and activity are increased in AD brain 
compared to control [15] as well as in the brains of trans-
genic mice models of AD, where it accumulates around 
amyloid plaques and in dystrophic neurites [16, 17]. In 
addition, a decrease in ADAM10 activity has been shown 
in AD patients when compared to control subjects [18].
An important issue for our understanding of the physi-
ological and pathological role of Aβ is to elucidate how 
its production is regulated. A potential regulatory mech-
anism for Aβ production is the subcellular localization 
of APP and its secretases. Knowledge about the subcel-
lular localization can open up for therapeutic opportu-
nities by targeting inhibitors to specific subcellular sites 
or by manipulating the trafficking of the proteins. The 
importance of protein and vesicle trafficking in AD is 
emphasized by the fact that risk genes for AD, identified 
in genome wide association studies, are involved in these 
processes [19].
BACE1 is active in acidic environments, mainly in 
endosomes, and is generally considered to be located 
presynaptically in neurons [17, 20–23]. ADAM10, on 
the other hand, is mainly regarded to be localized to 
Golgi and the plasma membrane and to be part of the 
postsynaptic density (PSD) [24–26]. Based on these ear-
lier studies, the amyloidogenic processing thus appears 
to take place presynaptically whereas the non-amyloi-
dogenic processing would be considered to occur post-
synaptically. However, using subcellular fractionation of 
rat brain and proximity ligation assay (PLA) in primary 
neurons, we have previously shown that both ADAM10 
and BACE1 are highly enriched in synaptic vesicles (SVs). 
Aβ can also be produced and stored in SVs, although we 
could not detect any enrichment of Aβ production in 
pure synaptic vesicles [27–29]. However, since primary 
neurons do not recapitulate the situation in adult brain 
and due to the fact that homogenization and subcellu-
lar fractionation can introduce artefacts, it would also 
be important to study the localization of ADAM10 and 
BACE1 in sections from intact adult brain. In addition, 
not only the presynaptic but also the postsynaptic locali-
zation of these enzymes should be investigated. Further-
more, no studies have, to our knowledge, investigated the 
localization of ADAM10 and BACE1 in human brain. 
Normal immunohistochemistry can never reach a spa-
tial resolution less than 200  nm and can therefore not 
provide detailed information about subcellular localiza-
tion. In addition, novel methods such as super-resolution 
microscopy are not yet fully developed to be used in 
brain tissue and are hampered by the extensive auto-flu-
orescence in postmortem aged human brain. Therefore, 
we used brightfield proximity ligation (PLA) as an alter-
native approach to investigate the proximity of ADAM10 
and BACE1, as well as their substrate APP, to the presyn-
aptic marker synaptophysin and the postsynaptic marker 
PSD-95. In PLA, secondary antibodies are conjugated to 
oligonucleotides that, if the proteins of interest are within 
40 nm distance from each other, can ligate to each other 
and be amplified and visualized [30]. The close proximity 
required thus provides much more detailed information 
than conventional immunohistochemistry. Using this 
method, as well as subcellular fractionation, we found 
that ADAM10 and BACE1 are located both pre- and 
postsynaptically in the adult rat brain as well as in human 
brain and that the distribution of the enzymes appears to 
be similar. Furthermore, we detected close proximity of 
APP with ADAM10, BACE1, synaptophysin and PSD95, 
suggesting that APP can be cleaved by ADAM10 and 
BACE1 both pre- and postsynaptically.
Results
In this study, we took advantage of the highly sensi-
tive method PLA to visualize the in  situ localization 
of ADAM10 and BACE1 in intact adult rat and human 
brain. With brightfield PLA, two proteins in close prox-
imity (< 40  nm) can be visualized in  situ. Thus, this 
method provides much more detailed information than 
normal immunohistochemistry and also circumvents 
the problem of auto-fluorescence, which is particularly 
prominent in aged human brain. We performed all PLA 
experiments in both hippocampal and cortical sections of 
rat and human brain, but since the results were similar, 
we have chosen only to present the data from the hip-
pocampal sections.
Detecting pre‑ and postsynaptic ADAM10 and BACE1 
in adult rat brain
To follow up on our previous study demonstrating close 
proximity of ADAM10 and BACE1 to the synaptic vesicle 
marker synaptophysin in mouse primary hippocampal 
neurons [27], we here investigated the synaptic localiza-
tion of ADAM10 and BACE1 in  situ in thin sections of 
intact adult rat hippocampus. In addition to investigating 
the proximity of these enzymes to the presynaptic marker 
synaptophysin, we also investigated the proximity to the 
postsynaptic marker PSD-95 and whether the pre- and 
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postsynaptic distribution differ between ADAM10 and 
BACE1. Using the brain from one rat, we performed PLA 
for the combinations ADAM10 + synaptophysin (Fig. 1a), 
ADAM10 + PSD-95 (Fig.  1b), BACE1 + synaptophysin 
(Fig.  1c) and BACE1 + PSD-95 (Fig.  1d). All these com-
binations gave rise to more signals compared to the 
negative controls where only one of the antibodies were 
used (Fig. 1e–g), revealing the presence of ADAM10 and 
BACE1 at both the pre- and postsynaptic side of the syn-
apse in adult rat brain hippocampus.
The number of PLA signals generated with PSD-95 
was generally higher than with synaptophysin for both of 
the secretases (Fig.  1a–g). This could indicate that both 
ADAM10 and BACE1 are present in higher amounts 
at the postsynaptic side. However, we cannot rule 
out that the higher number of signals is due to higher 
BACE1 + PSD-95
Synaptophysin, neg ctrl PSD-95, neg ctrl
ADAM10 + synaptophysin ADAM10 + PSD-95
BACE1 + synaptophysinc
e
a b
d
f
ADAM10, neg ctrlg BACE1, neg ctrlh
Fig. 1 Proximity ligation assay showing pre‑ and postsynaptic localization of ADAM10 and BACE1 in adult rat brain. Adult rat brain hippocampal 
sections were labelled with primary antibodies (anti‑ADAM10 or anti‑BACE1 made in rabbit and anti‑synaptophysin or anti‑PSD‑95 made in mouse) 
followed by secondary oligonucleotide‑linked probes. Each PLA signal (brown dot) denotes two proteins within 40 nm distance from each other; 
a ADAM10 and synaptophysin, b ADAM10 and PSD‑95, c BACE1 and synaptophysin and d BACE1 and PSD‑95. In the negative control samples 
only one primary antibody (anti‑synaptophysin (e), anti‑PSD‑95 (f), anti‑ADAM10 (g) or anti‑BACE1 (h)) was used. Brain tissue and cell nuclei were 
visualized by a nuclear stain solution containing Mayer´s haematoxylin. Each experiment was performed five times (technical replicates) and 
representative images are shown. Scale bar 20 µm
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concentrations of PSD-95 than synaptophysin and/or 
higher affinity of the PSD-95 antibody.
From this descriptive experiment we did not observe 
any differences between ADAM10 and BACE1 in the 
number of signals detected together with synaptophysin 
and PSD-95. Hence, the pre- and postsynaptic distribu-
tion of ADAM10 and BACE1 in adult rat brain appears 
to be similar.
Pre‑ and postsynaptic distribution of APP in adult rat brain
Apart from the localization of the secretases, we also 
elucidated the synaptic localization of the substrate APP 
using brightfield PLA. APP + synaptophysin (Fig.  2a) 
and APP + PSD-95 (Fig.  2b) resulted in higher number 
of signals than the negative control in which the primary 
antibodies were omitted (Fig.  2c). Thus, APP is in close 
proximity to both synaptophysin and PSD-95 in adult 
rat brain hippocampus (Fig. 2). Again, a higher number 
of signals was observed for PSD-95 than for synapto-
physin but it is evident that APP is located both pre- and 
postsynaptically in rat brain. In addition, we performed 
brightfield PLA of ADAM10 and BACE1 with their 
substrate APP and, as expected, concluded that both 
secretases are in close proximity to APP in adult rat brain 
hippocampus (Additional file 1: Figure S1).
Pre‑ and postsynaptic localization of ADAM10 and BACE1 
in fractionated rat brain
To corroborate our PLA results, we isolated pure SV and 
PSD fractions from adult rat brain and used western blot-
ting to assess the presence and potential enrichment of 
ADAM10 and BACE1 in these fractions. The purity of 
these fractions (e.g. absence of postsynaptic elements in 
the SV fraction and vice versa) has been shown previ-
ously [26, 27, 31]. To quantify the amounts of ADAM10 
and BACE1, we loaded different concentrations of the 
fractions on an SDS-PAGE gel to make standard curves 
from which to calculate the relative amounts of the 
secretases. In agreement with our previously published 
data [27], we observed enrichment of both ADAM10 
and BACE1 in the SV fractions compared to homogen-
ate (Fig.  3a). The enrichment of mature ADAM10 (pre-
dicted size 62–64 kDa [32]) in the SV fraction compared 
to homogenate was on average 95-fold (n = 4 different SV 
preparations, individual data: 200-fold, 110-fold, 42-fold 
and 27-fold) and the enrichment of BACE1 was on aver-
age 24-fold (n = 4 different SV preparations, individual 
data: 43-fold, 27-fold, 16-fold and ninefold) but varied 
considerably between preparations. In accordance with 
our above mentioned publication [27], we also observed 
a similar enrichment of APP C-terminal fragments 
(CTFs) in the SV fractions, while full length APP was less 
enriched (data not shown). Interestingly, only the mature 
form of ADAM10 was detected in the PSD fraction.
A qualitative analysis of the enrichment of ADAM10 
and BACE1 in the PSD fractions was carried out where 
different concentrations of homogenate and PSD fraction 
APP + synaptophysin
APP + PSD-95
Neg ctrlc
a
b
Fig. 2 Proximity ligation assay showing pre‑ and postsynaptic 
localization of APP in adult rat brain. Adult rat brain hippocampal 
sections were subjected to PLA and each signal (brown dot) 
generated denotes two proteins within 40 nm distance from each 
other. a APP and synaptophysin, b APP and PSD‑95. c Negative 
control with no primary antibodies. Brain tissue and cell nuclei 
were visualized by a nuclear stain solution containing Mayer´s 
haematoxylin. Each experiment was performed three times (technical 
replicates) and representative images are shown. Scale bar 20 µm
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were loaded on a SDS-PAGE. The results show that both 
enzymes are present in the postsynaptic fraction and that 
they are enriched to a similar degree (Fig. 3b).
Pre‑ and postsynaptic distribution of ADAM10 and BACE1 
in human brain
Since humans develop AD spontaneously whereas rats 
and mice do not, and since substantial translational 
problems between mouse models and human patients 
have been observed during the last years, it is important 
to also study human brain. We therefore performed the 
same sets of PLA experiments in human postmortem 
brain as we did in rat brain. Many PLA signals were gen-
erated when ADAM10 and BACE1 were probed against 
both synaptophysin (Fig. 4a–d) and PSD-95 (Fig. 4e–h) in 
AD or control brain hippocampus, whereas only limited 
number of signals were detected in the negative control 
samples where the primary antibodies had been omitted 
(Fig.  4i–j). We repeated the experiment in cortical sec-
tions from 3 AD and 3 control brains and in all cases we 
detected both pre- and postsynaptic localization of both 
ADAM10 and BACE1 (data not shown). Due to large 
inter-experimental variations, we were unfortunately not 
able to quantify potential differences in the pre- and post-
synaptic distribution of the secretases between AD and 
control brain. However, as for rat brain, no evident differ-
ences in the pre- and postsynaptic distribution between 
ADAM10 and BACE1 could be observed.
a
b
Fig. 3 Detection of ADAM10 and BACE1 in synaptic vesicle and postsynaptic density fractions of adult rat brain. Indicated amounts of total brain 
homogenate (H), synaptic vesicle (SV) (a) and postsynaptic density (PSD) (b) fractions were loaded on a gel and subjected to western blotting using 
ADAM10, BACE1, and synaptophysin (a) or PSD‑95 (b) antibodies. The SV fractionation was performed four times (from different pools of 20 rat 
brains) and a representative image is shown. The PSD fractionation was only performed once (from a pool of 30 rat brains)
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Fig. 4 Proximity ligation assay showing pre‑ and postsynaptic localization of ADAM10 and BACE1 in human postmortem AD and control brain 
hippocampus. Human control (ctrl) (a, c, e, g, i) and AD (b, d, f, h, j) hippocampal sections were subjected to PLA and each signal (brown dot) 
generated denotes two proteins within 40 nm distance from each other, here ADAM10 and synaptophysin (a, b), BACE1 and synaptophysin (c, 
d), ADAM10 and PSD‑95 (e, f) or BACE1 and PSD‑95 (g, h). Primary antibodies were excluded from the negative control sections (i, j). Brain tissue 
and cell nuclei were visualized by a nuclear stain solution containing Mayer´s haematoxylin. Each experiment was performed at least three times 
(technical replicates) and representative images are shown. Scale bar 20 µm
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Visualising pre‑ and postsynaptic APP in human brain
As in rat brain (Fig.  2), we detected PLA signals when 
investigating the proximity of APP and synaptophysin 
(Fig. 5a, b) as well as APP and PSD-95 (Fig. 5c, d) also in 
human AD and control hippocampus. On the contrary, 
very few signals were detected in the control experiments 
where the primary antibodies were omitted (Fig.  5e, f ). 
Again, we could unfortunately not quantify the results to 
compare AD to control. APP also co-localized with both 
ADAM10 and BACE1 in human AD and control brain 
hippocampus (Additional file 2: Figure S2).
Discussion
Due to the central role of Aβ in the pathology of AD 
and its toxic effects on synaptic function, it is essen-
tial to understand how its production is regulated. A 
key regulatory step for Aβ production is the subcellu-
lar location of APP and the secretases responsible for 
its initial processing. Thus, elucidating the location of 
these secretases is of major importance. Here we show 
that the α-secretase ADAM10, the β-secretase BACE1 
and their substrate APP are located both pre- and post-
synaptically with a similar distribution pattern.
The expression of both ADAM10 and BACE1 mRNA 
is widespread in the human brain [33, 34] and the pro-
tein level as well as the activity of BACE1 are increased 
in AD compared to control brain [15]. At the synapse, 
BACE1 is generally thought of as a pre-synaptic enzyme 
[17, 20–23] while ADAM10 is known to be present in 
the postsynaptic membrane [26, 35]. However, we have 
recently demonstrated that not only BACE1, but also 
ADAM10, is greatly enriched in the presynaptic com-
partment, more specifically in synaptic vesicles [27]. 
We have also previously shown that both ADAM10 and 
BACE1 are present in postsynaptic fractions of mouse 
Ctrl; APP + PSD-95 AD; APP + PSD-95
Ctrl; neg ctrl
Ctrl; APP + synaptophysin AD; APP + synaptophysin
AD; neg ctrl
b
c d
a
e f
Fig. 5 Proximity ligation assay showing pre‑ and postsynaptic localization of APP in human postmortem AD and control brain hippocampus. 
Human control (ctrl) (a, c) and AD (b, d) hippocampal sections were subjected to PLA and each signal (brown dot) generated denotes two proteins 
within 40 nm distance from each other. a, b APP and synaptophysin, c, d APP and PSD‑95. Primary antibodies were excluded from the negative 
control (e, f) sections. Brain tissue and cell nuclei were visualized by a nuclear stain solution containing Mayer´s haematoxylin. Each experiment was 
performed three times (technical replicates) and representative images are shown. Scale bar 20 µm
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brain and that their enrichment  correlates with the 
purity of the postsynaptic fraction [26].
Using a different fractionation protocol than ours, 
Pliássova et  al. [36, 37] found most ADAM10 to be 
postsynaptic and most BACE1 to be localized outside 
of the presynaptic active zone in rodent and human 
brain. They also report that APP mainly is presynaptic 
but also postsynaptic [36, 37] and that the synaptic lev-
els of APP were decreased during aging while ADAM10 
and BACE1 levels were not affected. Since the fraction-
ation protocols and the homogenization process can 
affect the results, we also used intact brain and assessed 
the in situ localization of the secretases and APP in the 
present study.
Because of the importance of the hippocampus for 
learning and memory and the fact that it is extensively 
affected by neuronal death as well as plaques and tangles 
in the AD brain [2, 38], we focused mainly on the hip-
pocampus in this study although all experiments were 
replicated in cortical sections as well. In both of these 
brain regions in rat and human adult brain we observed 
close proximity of both ADAM10 and BACE1 to the 
presynaptic marker synaptophysin as well as to the post-
synaptic marker PSD-95, indicating the presence of these 
secretases both pre- and postsynaptically. Although our 
study did not provide enough statistical power to allow 
for quantitative analysis, the proportion of pre- and post-
synaptic localization appeared similar for ADAM10 and 
BACE1. In line with this observation, Wang et  al. [39] 
reported that endogenous ADAM10 and BACE1 can 
physically interact with each other. Unfortunately, due 
to large inter-experimental variations, we were unable 
to quantify potential differences in the pre- and post-
synaptic distribution of the secretases between AD and 
control brain which was our initial intention. Reasons for 
this could be long postmortem intervals and difficulties in 
defining exactly the same region in the different sections.
The postsynaptic localization of BACE1 is particu-
larly interesting since some BACE1 substrates, e.g. Sei-
zure 6 (Sez6) [40, 41] have been found postsynaptically. 
The importance of Sez6 for postsynaptic functions of 
BACE1 was demonstrated by Zhu et  al. who used two-
photon microscopy to show that dendritic spine deficits 
introduced by BACE1 inhibition do not arise in  Sez6−/− 
dendrites [41]. Their study also suggests that the syn-
aptic deficits caused by BACE1 inhibitors would be of 
postsynaptic origin. On the other hand, ADAM10 also 
cleaves substrates which are located both pre- and post-
synaptically as well as transsynaptically [14]. Therefore, 
the pre- and postsynaptic localization of both ADAM10 
and BACE1 which we present evidence for in this study 
and in our previous studies [26, 27] is of physiological 
relevance.
Interestingly, in this study we show that the synap-
tic distribution pattern of ADAM10, BACE1 and APP 
seem to be similar both in rat and human brain. Our 
results also indicate that the proteins required for the 
initial step of Aβ generation are located both pre- and 
postsynaptically and that the balance between amyloi-
dogenic and non-amyloidogenic processing is similar in 
pre- and postsynaptic compartments. Yet, for Aβ to be 
generated, APP is cleaved not only by BACE1 but also by 
γ-secretase. Previous work in our laboratory using super-
resolution microscopy have demonstrated both pre- and 
postsynaptic localization of active γ-secretase [42]. How-
ever, the exact location of γ-secretase might be different 
from that of ADAM10 and BACE1 since the components 
of the γ-secretase complex are not enriched in SVs com-
pared to total brain homogenate [27]. Moreover, only 
few PLA signals were generated when we probed for the 
γ-secretase complex and synaptophysin in primary neu-
rons [27]. Nevertheless, a recent publication from our 
group showed, by using super-resolution microscopy, 
that a significant proportion of Aβ42 itself overlapped 
with the synaptic vesicle marker synaptophysin although 
other pre-synaptic structures might also contain Aβ [29].
The AD field is in urgent need of new and better 
therapies [43]. Reducing Aβ production by selectively 
inhibiting BACE1 cleavage of APP, and not of other 
substrates, is an attractive strategy. This can, for exam-
ple, be achieved by targeting inhibitors to subcellular 
locations with enriched levels of both BACE1 and APP. 
Likewise, increasing ADAM10 cleavage of APP, which 
consequently would reduce Aβ production, could also 
be an interesting approach. This and other studies inves-
tigating the subcellular and synaptic distribution of the 
APP cleaving secretases are therefore vital for the devel-
opment of such approaches and consequently for the 
advancement of AD therapy research.
Conclusions
We conclude that both ADAM10 and BACE1 as well as 
APP, can be found on both the pre- and postsynaptic side 
of the synapse and that the distribution between these 
locations are similar for ADAM10 and BACE1. Although 
descriptive and not quantitative, the findings presented 
in this study are of great relevance for the understanding 
of synaptic APP processing and hence for the develop-
ment of treatment strategies for AD.
Methods
Postmortem material
The use of human brain material in this study was con-
formed to the Declaration of Helsinki and approved 
by the regional ethical review board of Stockholm 
(2015/1803-31/2). Fresh frozen brain tissue from 
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hippocampus of one AD and one control subject and 
cortex of three AD and three control subjects was 
obtained from the Harvard Brain Tissue Resource 
Center at the NIH Brain Bank, US. All subjects were 
female, 71 to 81 years of age, and the tissues were col-
lected with postmortem delays of 8 to 27  h. The AD 
subjects fulfilled Braak stage V and VI while the control 
subjects were Braak stage I and II.
Animals
All animals used in this study were handled according 
to the Swedish, German or Italian national guidelines 
and the guidelines of Karolinska Institutet, the Univer-
sity of Göttingen and the University of Milano as well 
as the current European Law (Directive 2010/63/EU). 
Animals were maintained on a 12-h light/dark cycle in 
a temperature-controlled room (20–22  °C) in spacious 
cages with free access to food and water. Tubes were 
provided as hideouts and paper tissues were available 
for the rats’ occupation and nest building. The male 
Wistar rats (Charles River) used for PLA were directly 
sacrificed by increasing levels of carbon dioxide and 
were instantly decapitated. The Sprague–Dawley rats 
(Charles River) used for the SV-fractionation were 
sacrificed by cervical dislocation followed by decapi-
tation while the Sprague–Dawley rats (Charles River) 
used for the PSD-fractionation were anaesthetized 
with isoflurane (3–4%, inhalation for 2–3  min) before 
they were sacrificed by carbon dioxide and decapi-
tated. The use of rat brain in this study was approved 
by the Animal research ethical committee of southern 
Stockholm (S21-14) and the Italian Ministry of Health 
(#326/2015). No experiments were performed on live 
animals. For PLA, the brains were dissected out and 
immediately snap frozen in liquid nitrogen or isopen-
tane precooled to −  80  °C. A Leica CM 3050 cryostat 
was used to cut 10 µm thin brain sections which were 
mounted on Superfrost™ Plus Gold slides (Thermo 
Fisher Scientific) and stored at − 20 °C until use.
Antibodies and reagents
Primary antibodies for PLA and western blotting are 
described in Table 1. Secondary antibodies (horseradish 
peroxidase (HRP)-Goat anti-mouse and HRP-Goat anti-
rabbit) were purchased from Bio-Rad and GE Healthcare. 
Secondary antibodies conjugated to PLA probes were 
purchased from Sigma-Aldrich (Merck).
Proximity ligation assay
Brightfield PLA was essentially performed according 
to the protocol of the manufacturer (Sigma-Aldrich). 
Brain sections from Wistar rats or postmortem human 
tissue were fixed for 10 min at room temperature in 4% 
paraformaldehyde, washed with phosphate buffered 
saline (PBS) and permeabilized with 0.4% CHAPSO for 
another 10 min at room temperature. Endogenous perox-
idase activity was blocked with hydrogen peroxide solu-
tion by 10 min incubation at room temperature and the 
slices were then washed in washing solution A. Unspe-
cific binding sites for antibodies were blocked for 30 min 
with blocking solution at 37  °C and the slices were sub-
sequently incubated with primary antibodies overnight 
at 4 °C. The following day, secondary probes attached to 
oligonucleotides were added and, after washing, the oli-
gonucleotides of the bound probes where ligated, ampli-
fied and visualized by addition of the detection reagent 
and substrate solution. After addition of the nuclear stain 
solution, containing Mayer´s haematoxylin, the brain 
sections where dehydrated in ascending concentrations 
of ethanol and finally xylene and subsequently mounted. 
The PLA signals were detected using a light microscope 
(Nikon Eclipse E800M) and manually counted using 
the Image J software. As negative controls for the PLA 
experiments in Fig.  1, we omitted one of the primary 
antibodies. However, we found that similar amounts of 
signals appear in the negative controls when performing 
PLA without any primary antibodies. Hence, as negative 
control for the rest of the PLA experiments, we decided 
to totally exclude primary antibodies. All experiments 
in one group for the hippocampal experiments were 
Table 1 List of antibodies used for western blotting (WB) and proximity ligation assay (PLA)
Antibody name Company Dilution (WB) Dilution (PLA)
Anti‑ADAM10 Abcam (ab39153) 1:4000 1:4000
Anti‑Amyloid beta precursor protein C‑terminus 
[Y188]
Abcam (ab32136) 1:5000 1:5000
Anti‑APP C‑terminus [C1/6.1] BioLegend (802801) – 1:1000
Anti‑BACE1 Cell Signaling Technology (D10E5) 1:1000 1:200
Anti‑PSD‑95 Abcam (ab2723) – 1:20 000
Anti‑PSD‑95 Neuromab, k28/43 (75‑028) 1:1000 –
Anti‑Synaptophysin Enzo (VAM‑SV011F) 1:10 000 1:3000
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performed on brain sections from the same rat, AD or 
control brain, but the experiments were also performed 
in cortical sections from several brains (three AD and 
three control brains).
Preparation of pure synaptic vesicles
Pure synaptic vesicles (SVs) were prepared from 
Sprague–Dawley rat forebrain as described before [31, 
44]. Briefly, 20 rat brains were homogenized in homog-
enization buffer containing 320 mM sucrose and 4 mM 
HEPES–KOH (pH 7.4) in a Teflon-glass homogenizer (10 
strokes at 900  rpm). The resulting homogenate (H) was 
centrifuged for 10 min at 1000g to remove cell debris and 
pellet nuclei (P1). Supernatants (S1) were pooled and 
centrifuged for 15 min at 10,000 g to obtain a crude syn-
aptosomal fraction (P2), and crude brain cytosol (S2).
Synaptosomes were osmotically lysed by adding 9 
vol. of ice-cold  ddH2O containing protease-inhibitors 
(Roche) and homogenized in a Teflon-glass homogenizer 
(3 strokes at 2000  rpm). The lysed synaptosomes were 
centrifuged for 20  min at 25,000g at 4  °C to spin down 
lysed synaptosomal membranes (LP1). The SV contain-
ing supernatant (LS1), containing SVs and synaptosomal 
cytosol, was further ultracentrifuged for 2 h at 200,000g 
to separate SVs (LP2) from the synaptic cytosolic frac-
tion (LS2). The LP2 fraction was resuspended in 40 mM 
sucrose and subjected to a continuous sucrose gradient 
centrifugation (from 0.05  M sucrose to 0.8  M sucrose) 
for 4 h at 82,500g and 4 °C. SVs from the gradient inter-
face were further purified using size-exclusion chroma-
tography on a CPG-column (using controlled pore glass 
beads), which separates large membrane structures (Peak 
1) from SVs.
Purification of postsynaptic density
To isolate PSDs from Sprague Dawley rat hippocampi, a 
modification of the method of Carlin et al. [45] was used 
as described by Gardoni et  al. [46, 47]. Homogeniza-
tion of 30 rat hippocampi was carried out by 10 strokes 
in a Teflon-glass homogenizer in 4 volumes of 0.32  M 
sucrose containing 1  mM HEPES, 1  mM  MgCl2, 1  mM 
 NaHCO3, 1  mM NaF and 0.1  mM phenylmethylsulfo-
nylfluoride (PMSF) (pH 7.4) in the presence of protease 
inhibitors (Complete; Roche/ Phosphatase Inhibitor 
Cocktail 2; Sigma-Aldrich), and centrifuged at 1000×g 
for 5  min at 4  °C. The supernatant was centrifuged at 
13,800×g for 15  min at 4  °C to obtain a fraction con-
taining mitochondria and synaptosomes. The pellet was 
resuspended in 2.4 volumes of 0.32 M sucrose containing 
1 mM HEPES and Complete, overlaid on a sucrose gra-
dient (0.85–1.0–1.2 M), and centrifuged at 82,500×g for 
2 h at 4 °C. The fraction between 1.0 and 1.2 M sucrose 
was removed, diluted with an equal volume of 0.5% 
TritonX-100 in 0.16 M sucrose containing 1 mM HEPES 
and stirred at 4  °C for 15 min. This solution was centri-
fuged at 82,500×g for 45  min. The resulting pellet was 
resuspended in 0.32 M sucrose containing 1 mM HEPES 
and Complete buffer, overlaid on a sucrose gradient (1.0–
1.5–2.1 M), and centrifuged at 100,000×g for 2 h at 4 °C. 
The fraction between 1.5 and 2.1 M sucrose was removed 
and diluted with an equal volume of 1% TritonX-100, 
150 mM KCl and Complete. PSDs were collected by cen-
trifugation at 100,000×g at 4 °C for 45 min and stored at 
− 80 °C.
SDS‑PAGE and western blotting
Different concentrations of SV or PSD preparations and 
matching total brain homogenate were separated by 
SDS-PAGE on 4–12% polyacrylamide Bis–Tris gels (SV) 
(Invitrogen) or 7% SDS-PAGE/Tris–Glycine gels (PSD) 
and transferred to PVDF (SV) or nitrocellulose mem-
branes (PSD) (Bio-Rad). The membranes were incubated 
with primary antibodies (Table  1) followed by second-
ary antibodies coupled to HRP (GE-Healthcare or Bio-
Rad). Signals were visualized with SuperSignal West Pico 
enhanced chemiluminescent reagent (Pierce), Immobilon 
Western Chemiluminescent HRP Substrate (Millipore) 
or Clarity™ Western ECL substrate (Bio-Rad) and expo-
sure to film (GE-Healthcare), LAS-3000 CCD camera 
(Fujifilm) or computer-assisted imaging (ChemiDoc sys-
tem and Image lab 4.0 software; Bio-Rad).
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Additional file 1. Proximity ligation assay showing co‑localization of 
ADAM10 and BACE1 with their substrate APP in adult rat brain. Adult 
rat brain hippocampal sections were subjected to PLA and each signal 
(brown dot) generated denotes two proteins within 40 nm distance from 
each other. (a) APP and ADAM10, (b) APP and BACE1. (c) Negative control 
with no primary antibodies. Brain tissue and cell nuclei were visualized by 
a nuclear stain solution containing Mayer´s haematoxylin. Each experi‑
ment was performed three times and representative images are shown. 
Scale bar 20 µm. 
Additional file 2. Proximity ligation assay showing co‑localization of 
ADAM0 and BACE1 with their substrate APP in human post mortem AD 
and control brain hippocampus. Human control (ctrl) (a, c and e) and 
AD (b, d and f ) hippocampal sections were subjected to PLA and each 
signal (brown dot) generated denotes two proteins within 40 nm distance 
from each other. (a–b) APP and ADAM10, (c–d) APP and BACE1. Primary 
antibodies were excluded from the negative control (e–f ) sections. Brain 
tissue and cell nuclei were visualized by a nuclear stain solution contain‑
ing Mayer´s haematoxylin. Each experiment was performed three times 
and representative images are shown. Scale bar 20 µm.
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